An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
An analysis of SEER data identified the risk for these cardiovascular events and the common related causes of death among patients with MM.
A study presented at the 2018 ASCO Annual Meeting investigated the mortality risk for patients with multiple myeloma who develop VTE.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
Although unprovoked VTE may be a sign of occult cancer, results of a meta-analysis showed no benefit to extensive cancer screening in these patients.
An evaluation of the association of tissue factor, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE helps determine their predictive value for patients at high risk.
This review examines the epidemiology and pathophysiology of cancer-associated thrombosis, risk factors, and new predictive biomarkers for venous thromboembolism (VTE).
